Inovio Pharmaceuticals (INO) Other Non Operating Income (2010 - 2026)
Inovio Pharmaceuticals (INO) posted Other Non Operating Income of -$285490.0 for Q1 2026, down 324520.45% sequentially from $88.0 in Q4 2025, and down 59130.29% YoY from N/an in Q1 2025.
Inovio Pharmaceuticals (INO) Other Non Operating Income (2010 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported Other Non Operating Income for 11 years, with the latest figure at -$285490.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 59130.29% year-over-year to -$285490.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.9 million (down 17.92% YoY) and the FY2025 annual result came in at -$2.6 million, up 16.5% from the prior year.
- Other Non Operating Income fell to -$285490.0 in Q1 2026 per INO's latest filing, from $88.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $7571.0 in Q2 2024 and troughed at -$2.8 million in Q4 2022.
- A 5-year average of -$862599.7 and a median of -$682218.0 in 2024 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2024 and 2026: Other Non Operating Income surged 100.53% in 2024, then slumped 59130.29% in 2026.
- Over 5 years, Other Non Operating Income stood at -$2.8 million in 2022, then soared by 68.86% to -$860908.0 in 2023, then slumped by 121.77% to -$1.9 million in 2024, then jumped by 100.0% to $88.0 in 2025, then slumped by 324520.45% to -$285490.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$285490.0, $88.0, and -$1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Inovio Pharmaceuticals | 96.32 Mn | 96.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.71 Mn |
| Mar 31, 2026 | -285,490.00 |
| Dec 31, 2025 | 88.00 |
| Sep 30, 2025 | -1.94 Mn |
| Jun 30, 2025 | -703,183.00 |
| Mar 31, 2025 | -482.00 |
| Dec 31, 2024 | -1.91 Mn |
| Sep 30, 2024 | -579,819.00 |
| Jun 30, 2024 | 7,571.00 |
| Mar 31, 2024 | -682,218.00 |
| Dec 31, 2023 | -860,908.00 |
| Sep 30, 2023 | 2,854.00 |
| Jun 30, 2023 | -1.43 Mn |
| Mar 31, 2023 | -2.43 Mn |
| Dec 31, 2022 | -2.76 Mn |
| Sep 30, 2022 | -940,778.00 |
| Jun 30, 2022 | -3,048.00 |
| Mar 31, 2022 | -153,468.00 |
| Dec 31, 2021 | 177,598.00 |
| Sep 30, 2021 | -28,486.00 |